YD Bio Limited Ordinary Shares (YDES) Revenue History
Annual and quarterly revenue from 2020 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
YDES Revenue Analysis (2020–2024)
As of March 5, 2026, YD Bio Limited Ordinary Shares (YDES) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q2 2025) recorded $0 in revenue.
Looking at the longer-term picture, YDES's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $510,360 in 2024, representing a new all-time high.
When compared to Healthcare sector peers including CAI (+144.9% YoY), VCYT (+16.0% YoY), and ADPT (+42.6% YoY). Compare YDES vs CAI →
Peer Comparison
Compare YDES's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| YDESCurrent | $0 | - | - | -286.5% | |
 CAI | $812M | +144.9% | +14.3% | 5.6% | |
 VCYT | $517M | +16.0% | +34.5% | 11.2% | |
 ADPT | $179M | +42.6% | +16.0% | -90.8% | |
 CDIO | $34,890 | -55.8% | - | -23977.9% | |
 SEER | $14M | +14.5% | +160.6% | -717.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $510K | +45.8% | $155K | 30.4% | $-1,461,930 | -286.5% |
| 2023 | $350K | - | $153K | 43.8% | $-9,847 | -2.8% |
| 2022 | $0 | - | $0 | - | $-2,323,153 | - |
| 2021 | $0 | - | $0 | - | $-1,722,364 | - |
| 2020 | $0 | - | $0 | - | $-344,223 | - |
See YDES's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs YDES Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare YDES vs LLY
See how YDES stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is YDES's revenue growth accelerating or slowing?
YDES TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is YDES's long-term revenue growth rate?
YD Bio Limited Ordinary Shares's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is YDES's revenue distributed by segment?
YDES reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.